Option chain shows key data for Numinus Wellness's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Numinus Wellness.

Numinus Wellness (OTC:NUMIF) Stock, Option Chain

Numinus Wellness Inc develops proprietary, psychedelic-centered, therapeutic products and services through its laboratory and research & development processes. The company's clinic network consists of Numinus Health, Mindspace Services, and the Neurology Center of Toronto. Its services include Ketamine-assisted psychotherapy for depression, neurological care, psychotherapy, and counseling by registered psychologists among others. The company's operating segments are; Clinical research operations, Canadian clinic network, US clinic network and Corporate. The majority of the revenue for the company is generated from US clinic network segment. Geographically, the company has its presence in United States and Canada.

Cannabis

News

Psychedelics

NUMIF

Numinus Wellness sells U.S. clinics to Stella for $3.5M, in a partnership to develop tech-driven solutions for mental health providers.

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

Regulations

Health Care

ATAI

CMPS

MBIO

AWAKNF

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?

finance and psychedelics (anaterate, sergeitokmakov by Pixabay)(3)

Earnings

CSE:MBAI

TSX:NUMI

Psychedelics-focused mental health care company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), announced on Thursday its third quarter financial results for the three months ended May 31, 2024.&#34;In the third quarter of 2024, we continued to make progress on our program to transition Numinus to an operationally lean company prepared to benefit from the anticipated growth in psychedelic therapy. Key to the program is achieving profitability with our existing operations and leveraging our significant experience and expertise to opportunities in the broad market,&#34; Payton Nyquvest, Numinus founder and CEO, said.

Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit

NUMINUS WELLNESS INC by Numinus Wellness Inc.

Numinus Wellness Inc

Citigroup analyst Christopher Allen maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Neutral and raises the price target from $80 to $85.

Price Target

Analyst Ratings

SCHW

Citigroup Maintains Neutral on Charles Schwab, Raises Price Target to $85

The Offering is expected to close on or about January 23, 2025, subject to the satisfaction of customary closing conditions.&nbsp;

MCTR

CTRL Group Prices $8M Initial Public Offering Of 2M Common Shares At $4/Share

WIIM

RVSN

Rail Vision shares are trading higher after the company announced a binding MoU with Sujan Ventures to introduce its safety systems to the Indian railway market.

FCEL

FuelCell Energy shares are trading higher after the company announced plans to build a 7.4 MW fuel cell power plant in Hartford, Connecticut, expected to add over $160 million to its generation backlog.

HC Wainwright &amp; Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and raises the price target from $36 to $39.

AVBP

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $39

ALLY

Ally Financial shares are trading higher after the company reported better-than-expected Q4 financial results and announced it will divest its credit card unit to CardWorks.

Deutsche Bank analyst Steve Powers maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $80 to $78.

Deutsche Bank Maintains Hold on Estee Lauder Cos, Lowers Price Target to $78

Financing

IESC

IES Announced That It Has Amended And Restated Its Existing Credit And Security Agreement, Increasing The Commitment Amount Of The Revolving Credit Facility To $300M From $150M And Extending The Maturity Date To January 21, 2030 While Expanding The Size Of The Lending Group

Deutsche Bank analyst Steve Powers maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Buy and lowers the price target from $184 to $178.

Deutsche Bank Maintains Buy on PepsiCo, Lowers Price Target to $178

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $965 to $1150.

NFLX

Macquarie Maintains Outperform on Netflix, Raises Price Target to $1150

Deutsche Bank analyst Stephen Powers maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Hold and lowers the price target from $67 to $62.

MDLZ

Deutsche Bank Maintains Hold on Mondelez International, Lowers Price Target to $62

Rail Vision Announced The Signing Of A Binding Memorandum Of Understanding With Sujan Ventures, A Division Of The Esteemed Sujan Group To The Indian Rail Industry

Northland Capital Markets analyst Michael Latimore maintains Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) with a Outperform and raises the price target from $13 to $18.

GRRR

Northland Capital Markets Maintains Outperform on Gorilla Tech Gr, Raises Price Target to $18

Barclays analyst Jason Goldberg maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Underweight and raises the price target from $59 to $61.

ZION

Barclays Maintains Underweight on Zions Bancorp, Raises Price Target to $61

Northland Capital Markets analyst Gus Richard reiterates Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Outperform and raises the price target from $144 to $160.

Reiteration

Northland Capital Markets Reiterates Outperform on Seagate Tech Hldgs, Raises Price Target to $160

REKR

Rekor Systems' AI-Powered Scout Platform Secures Role In $13M New Jersey Public Safety Upgrade

AGYS

Agilysys shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY25 revenue guidance below estimates.

HC Wainwright &amp; Co. analyst Robert Burns maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Buy and raises the price target from $17 to $21.

REPL

HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $21

Barclays analyst Nicholas Campanella maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Overweight and lowers the price target from $71 to $69.

Barclays Maintains Overweight on Xcel Energy, Lowers Price Target to $69

Barclays analyst Benjamin Budish maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Overweight and raises the price target from $95 to $96.

Comments

Numinus Wellness

Numinus Wellness (NUMIF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga